Evidence map›Paper›PMID 34011277›Full record

ArticleBMC molecular and cell biology2021

sFLT01 modulates invasion and metastasis in prostate cancer DU145 cells by inhibition of VEGF/GRP78/MMP2&9 axis.

Sepideh Taghizadeh, Zahra-Soheila Soheili, Mehdi Sadeghi, Shahram Samiei, Ehsan Ranaei Pirmardan, Ali Kashanian, Fahimeh Zakeri, Hamid Latifi-Navid, Hoda Shams Najafabadi

Open access · goldAbstract read
In one paragraph

Article in BMC molecular and cell biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sepideh TaghizadehDepartment of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology, 14965/161, Tehran, Iran.
Zahra-Soheila SoheiliDepartment of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology, 14965/161, Tehran, Iran. soheili@nigeb.ac.ir.
Mehdi SadeghiDepartment of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology, 14965/161, Tehran, Iran.
Shahram SamieiBlood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Ehsan Ranaei PirmardanMolecular Biomarkers Nano-Imaging Laboratory, Brigham and Women's Hospital, Department of Radiology Harvard Medical School, Boston, MA, USA.
Ali KashanianDepartment of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology, 14965/161, Tehran, Iran.
Fahimeh ZakeriDepartment of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology, 14965/161, Tehran, Iran.
Hamid Latifi-NavidDepartment of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology, 14965/161, Tehran, Iran.
Hoda Shams NajafabadiDepartment of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology, 14965/161, Tehran, Iran.
National Institute of Genetic Engineering and Biotechnology · IRBrigham and Women's Hospital · USHigh Institute for Education and Research in Transfusion Medicine · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbout 90% of cancer-related deaths are due to metastasis of cancer cells, and angiogenesis is a critical step in this process. sFLT01 is a novel fusion protein and a dual-targeting agent that neutralizes both VEGF and PlGF proangiogenic activities. GRP78 dual effect in tumor growth and angiogenesis could be activated under VEGF stimulation. The current study was designed to investigate the inhibitory impact of sFLT01 protein on VEGF/GRP78 axis. To this point, sFLT01 construct was synthesized, recombinant plasmid was expressed in eukaryotic host cells, sFLT01-HisTag protein was extracted and analyzed. The functional activity of sFLT01 on VEGF-enhanced tube formation and angiogenesis of HUVEC cells were examined. Eventually, the inhibitory impact of sFLT01 on growth, invasiveness, and migration of human prostate cancer cell line, DU145, was assessed. Real-time PCR evaluated the level of GRP78 and its effect on the downstream factors; matrix metallopeptidase proteins 2&9 (MMP2&9) along with tissue inhibitor of metalloproteinase proteins1&2 (TIMP1&2) under sFLT01 stimulation.

resultsAccording to the data, sFLT01 protein showed modulatory impact on proliferation, invasion, and migration of DU145 cells along with the potential of HUVECs angiogenesis. Real-Time PCR analysis depicted a significant downregulation in GRP78, MMP2 and MMP9 transcripts' levels, and a subsequent elevation of TIMP1 and TIMP2 expression under sFLT01 stimulation was detected.

conclusionOverall, these data indicated that the inhibitory impact of sFLT01 on cancer cells growth and invasiveness could be mediated through the modulation of VEGF/GRP78/MMP2&9 axis and activation of TIMPs.

Indexed as

Angiogenesis InhibitorsRecombinant Fusion ProteinsCell Line, TumorCell MovementCell SurvivalEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHEK293 CellsHumansHuman Umbilical Vein Endothelial CellsMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9Neoplasm InvasivenessProstatic NeoplasmsSignal TransductionAngiogenesis InhibitorsEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHSPA5 protein, humanMatrix Metalloproteinase 2Matrix Metalloproteinase 9MMP2 protein, humanMMP9 protein, humanRecombinant Fusion ProteinssFLT01 fusion proteinVascular Endothelial Growth Factor AAngiogenesisGRP78Prostate cancersFLT01VEGF

Identifiers

PMID34011277
PMCPMC8135984
OpenAlexW3129598557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.